Ademi LLP is investigating Prometheus (NASDAQ: RXDX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.
Ademi LLP alleges Prometheus’s financial outlook and prospects are excellent and yet Prometheus’s shareholders are expected to receive only $200.00 per share in cash for a total equity value of approximately $10.8 billion.. The transaction agreement unreasonably limits competing bids for Prometheus by imposing a significant penalty if Prometheus accepts a superior bid. Prometheus insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Prometheus’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Prometheus.